Larvol Delta - 23andMe-Announces-First-Patient-Dosed-for-the-Phase-2a-Portion-of-its-Phase-12a-Study-of-23ME00610-an-Investigational-Antibody-Targeting-CD200R1-in-Patients-with-Advanced-Solid-Malignancies

23ME-00610 - 23andMe

https://www.globenewswire.com/news-release/2023/02/28/2616881/0/en/23andMe-Announces-First-Patient-Dosed-for-the-Phase-2a-Portion-of-its-Phase-1-2a-Study-of-23ME-00610-an-Investigational-Antibody-Targeting-CD200R1-in-Patients-with-Advanced-Solid-M.html

Feb 28, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next